Johnston Lori A

SEC source: 0001127602-22-008137 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,881

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 690 RSUs which will vest on 4/27/2022; 1,361 RSUs which will vest in installments of 670 on 5/3/2022 and 691 on 5/3/2023; 5,226 RSUs which will vest in installments of 2,574 on 11/1/2022 and 2,652 on 11/1/2023; 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024; and 3,296 RSUs which vest in installments of 1,087 on 4/30/2023, 1,088 on 04/30/2024 and 1,121 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 785 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-028365 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,269

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 690 RSUs which will vest on 4/27/2022; 1,361 RSUs which will vest in installments of 670 on 5/3/2022 and 691 on 5/3/2023; 5,226 RSUs which will vest in installments of 2,574 on 11/1/2022 and 2,652 on 11/1/2023; 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024; and 3,296 RSUs which vest in installments of 1,087 on 4/30/2023, 1,088 on 04/30/2024 and 1,121 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 668 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015360 · form4.xml · nonDerivative · entry 3

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,365

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 690 RSUs which will vest on 4/27/2022; 1,361 RSUs which will vest in installments of 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024; and 3,296 RSUs which vest in installments of 1,087 on 4/30/2023, 1,088 on 04/30/2024 and 1,121 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 564 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-015360 · form4.xml · nonDerivative · entry 2

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,700

SEC source: 0001127602-21-015360 · form4.xml · derivative · entry 4

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,623

Underlying: Common Stock · 28,623 shares

Expires 2031-04-30

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-015360 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,055

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/30/2023, 4/30/2024 and 4/30/2025, respectively.

SEC source: 0001127602-21-014601 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,759

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which will vest on 5/1/2021; 690 RSUs which will vest on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 682 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-011712 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,104

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 742 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-009480 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,682

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 561 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-21-004798 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,074

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 561 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015862 · form4.xml · derivative · entry 2

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,799

Underlying: Common Stock · 24,799 shares

Expires 2030-05-05

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

SEC source: 0001127602-20-015862 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,268

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/5/2022, 5/5/2023 and 5/5/2024, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023; and 2,961 RSUs which vest in two installments of 977 on 5/5/2022 and 5/5/2023, and one installment of 1,007 on 5/5/2024. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 422 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-015546 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,307

F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 670 RSUs which vest on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 422 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-014696 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,642

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 1,359 RSUs which vest in installments of 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 479 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-011868 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,977

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 518 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-009709 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,517

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 406 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-20-004983 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,094

F1 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,199 RSUs which vest on 2/7/2021; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 406 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-031966 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,457

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 11/1/2021, 11/1/2022 and 11/1/2023, respectively.

F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022; 2,030 RSUs which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023; and 7,799 RSUs which will vest in installments of 2,573 on 11/1/2021, 2,574 on 11/1/2022 and 2,652 on 11/1/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 411 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017649 · form4.xml · derivative · entry 2

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,722

Underlying: Common Stock · 17,722 shares

Expires 2029-05-03

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

SEC source: 0001127602-19-017649 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,535

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/3/2021, 5/3/2022 and 5/3/2023, respectively.

F2 · balance_after: These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022; and 2,030 which will vest in installments of 669 on 5/3/2021, 670 on 5/3/2022 and 691 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 288 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-017340 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,505

F1 · balance_after: These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,319 RSUs which vest in installments of 649 5/1/2020 and 670 on 5/1/2021; and 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 288 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-19-005204 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,794

F1 · balance_after: These share include the following RSUs granted under the Company's equity plans: 2,398 RSUs which vest in two equal installments of 1,199 on 2/7/2020 and 2/7/2021, respectively; 1,968 RSUs which vest in two installments of 649 on each of 5/1/2019 and 5/1/2020 and one installment of 670 on 5/1/2021; and 2,028 RSUs which vest in three installments of 669 on 4/27/2020, 669 on 4/27/2021 and 690 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 272 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-18-015840 · form4.xml · derivative · entry 2

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,615

Underlying: Common Stock · 15,615 shares

Expires 2028-04-27

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

SEC source: 0001127602-18-015840 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,085

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 4/27/2020, 4/27/2021 and 4/27/2022, respectively.

F2 · balance_after: These share include the following RSUs granted under the Company's equity plans: 3,597 RSUs which vest in three equal installments of 1,199 on 2/7/2019, 2/7/2020 and 2/7/2021, respectively; and 1,968 RSUs which vest in two installments of 649 on each of 5/1/2019 and 5/1/2020 and one installment of 670 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 175 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-18-004483 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,017

F1 · balance_after: These share include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,597 RSUs which vest in three equal installments of 1,199 on 2/7/2019, 2/7/2020 and 2/7/2021, respectively; and 1,968 RSUs which vest in two installments of 649 on each of 5/1/2019 and 5/1/2020 and one installment of 670 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F2 · balance_after: These shares include 135 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-17-016753 · form4.xml · derivative · entry 2

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,429

Underlying: Common Stock · 17,429 shares

Expires 2027-05-01

F4 · derivative.exercise_date: These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively.

SEC source: 0001127602-17-016753 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,322

F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three installments of 33%, 33% and 34% on 5/1/2019, 5/1/2020 and 5/1/2021, respectively.

F2 · balance_after: These share include the following RSUs granted under the Company's equity plans: 4,795 RSUs which vest in one installment of 1,198 on 2/7/2018 and three equal installments of 1,199 on 2/7/2019, 2/7/2020 and 2/7/2021, respectively; and 1,968 RSUs which vest in two installments of 649 on each of 5/1/2019 and 5/1/2020 and one installment of 670 on 5/1/2021. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

F3 · balance_after: These shares include 31 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

SEC source: 0001127602-17-004866 · form4.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · SVP, HR

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,323

F1 · shares: The Restricted Stock Units were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in four annual installments of 25% each on 2/7/2018, 2/7/2019, 2/7/2020 and 2/7/2021.

SEC source: 0001306830-16-000423 · wf-form4_147872722176502.xml · derivative · entry 3

Johnston Lori A · CIK 0001558616 · EVP & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Common Stock · 57,085 shares

Expires 2019-10-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Granted pursuant to the Company's 2009 Global Incentive Plan, as Amended and Restated April 19, 2012. The options vested with respect to 33.3% of the options on each of October 17, 2013 and October 17, 2014, and with respect to 33.4% of the options on October 17, 2015.

SEC source: 0001306830-16-000423 · wf-form4_147872722176502.xml · nonDerivative · entry 2

Johnston Lori A · CIK 0001558616 · EVP & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,816

F1 · price: The reported price in this line is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $71.75 to $73.09. The reporting person will provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price.

SEC source: 0001306830-16-000423 · wf-form4_147872722176502.xml · nonDerivative · entry 1

Johnston Lori A · CIK 0001558616 · EVP & CAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.